论文部分内容阅读
目的探讨曲美他嗪在尿毒症合并慢性充血性心力衰竭治疗中的临床疗效。方法选择新乡市中心医院2013年1月到2014年12月收治的尿毒症合并慢性充血性心力衰竭患者68例,将其随机分成观察组与对照组各34例,对照组患者给予β-受体阻滞剂、促进红细胞生成素、血管紧张素Ⅱ受体拮抗剂、蔗糖铁等常规治疗,观察组患者在对照组患者的治疗基础上加用曲美他嗪治疗,分别对比两组患者的临床疗效、治疗前后6min步行的距离以及不良反应。结果观察组患者的临床疗效明显高于对照组患者的临床疗效。治疗前两组患者6min步行的距离差异不明显,治疗后观察组患者6min步行的距离明显高于对照组患者6min步行的距离。两组患者治疗后均未出现严重不良反应,实验室检查未出现异常情况。结论曲美他嗪在尿毒症合并慢性充血性心力衰竭的治疗中疗效显著,无严重不良反应,安全可靠。
Objective To investigate the clinical efficacy of trimetazidine in the treatment of uremia with chronic congestive heart failure. Methods Sixty-eight patients with uremia and chronic congestive heart failure admitted to Xinxiang Central Hospital from January 2013 to December 2014 were randomly divided into observation group (34 cases) and control group (34 cases), patients in control group Blockers, promoting erythropoietin, angiotensin Ⅱ receptor antagonist, iron sucrose and other conventional treatment, the observation group patients in the control group based on the treatment with trimetazidine treatment, respectively, compared the two groups of patients with clinical Curative effect, 6min walk distance and adverse reaction before and after treatment. Results The clinical efficacy of the observation group was significantly higher than that of the control group. Before treatment, there was no significant difference in the distance between the two groups in 6min walking. The distance of 6min walk in observation group was significantly higher than that in control group after 6min walk. No serious adverse reactions occurred in both groups after treatment, and no abnormalities were found in laboratory tests. Conclusion Trimetazidine is effective in the treatment of uremia complicated with chronic congestive heart failure without serious adverse reactions and is safe and reliable.